Etanercept

Etanercept Reactions 1704, p156 - 2 Jun 2018 Retroperitoneal fibrosis: case report An adult man [age at reaction onset not stated] developed retroperitoneal fibrosis (RPF) during long-standing treatment with etanercept for spondyloarthritis [route not stated]. The man was diagnosed with seronegative spondyloarthritis at the age of 31 years. He had received initial therapy for two years. However due to inefficacy, he was switched to etanercept 50 mg/week. Approximately ten years later, he developed acute low back pain with fever. Subsequent investigations revealed elevated acute phase reactants and raised creatinine level. An abdominal USG showed hydronephrosis and a CT scan revealed an enlarged left kidney caused by hydroureteronephrosis secondary to fibrotic stenosis of the ipsilateral ureter. The man was then admitted and subsequently underwent left ureterolysis and omentoplasty with insertion of double-J stent in the left ureter. A biopsy of the peritoneal and retroperitoneal tissue samples revealed a fibrotic tissue with marked chronic inflammatory changes, which was consistent with RPF. The etanercept therapy was discontinued, and he was treated with methylprednisolone. The low back pain resolved and the inflammatory markers were also normalised. The methylprednisolone therapy was tapered off simultaneously. Author comment: "Nonetheless, given the lack of knowledge about the pathogenesis of RPF and taking into account spondyloarthritis remission on adalimumab without worsening of RPF in our patient. . .a possible difference between etanercept and monoclonal antibodies (adalimumab and infliximab) in the development of RPF may be postulated." "Herein, we describe a case of RPF following a long-standing treatment with etanercept for spondyloarthritis." Manganelli S, et al. Retroperitoneal fibrosis following a long-standing etanercept treatment in a spondyloarthritis patient. Joint Bone Spine 85: 389-390, No. 3, May 2018. Available from: URL: https://doi.org/10.1016/j.jbspin.2017.05.024 - Italy 803323377 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Etanercept

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/etanercept-7hc8vQ2Tu4
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46799-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p156 - 2 Jun 2018 Retroperitoneal fibrosis: case report An adult man [age at reaction onset not stated] developed retroperitoneal fibrosis (RPF) during long-standing treatment with etanercept for spondyloarthritis [route not stated]. The man was diagnosed with seronegative spondyloarthritis at the age of 31 years. He had received initial therapy for two years. However due to inefficacy, he was switched to etanercept 50 mg/week. Approximately ten years later, he developed acute low back pain with fever. Subsequent investigations revealed elevated acute phase reactants and raised creatinine level. An abdominal USG showed hydronephrosis and a CT scan revealed an enlarged left kidney caused by hydroureteronephrosis secondary to fibrotic stenosis of the ipsilateral ureter. The man was then admitted and subsequently underwent left ureterolysis and omentoplasty with insertion of double-J stent in the left ureter. A biopsy of the peritoneal and retroperitoneal tissue samples revealed a fibrotic tissue with marked chronic inflammatory changes, which was consistent with RPF. The etanercept therapy was discontinued, and he was treated with methylprednisolone. The low back pain resolved and the inflammatory markers were also normalised. The methylprednisolone therapy was tapered off simultaneously. Author comment: "Nonetheless, given the lack of knowledge about the pathogenesis of RPF and taking into account spondyloarthritis remission on adalimumab without worsening of RPF in our patient. . .a possible difference between etanercept and monoclonal antibodies (adalimumab and infliximab) in the development of RPF may be postulated." "Herein, we describe a case of RPF following a long-standing treatment with etanercept for spondyloarthritis." Manganelli S, et al. Retroperitoneal fibrosis following a long-standing etanercept treatment in a spondyloarthritis patient. Joint Bone Spine 85: 389-390, No. 3, May 2018. Available from: URL: https://doi.org/10.1016/j.jbspin.2017.05.024 - Italy 803323377 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off